RWM
ATRA icon

Raffa Wealth Management’s Atara Biotherapeutics ATRA Stock Holding History

Raffa Wealth Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed -$672 – 288
2017
Q2 		$672 Hold
2
– – ﹤0.01% 385
2017
Q1 		$986 Hold
2
– – ﹤0.01% 326
2016
Q4 		$682 Buy
2
+1
+100% +$423 ﹤0.01% 595
2016
Q3 		$513 Hold
1
– – ﹤0.01% 716
2016
Q2 		$540 Hold
1
– – ﹤0.01% 647
2016
Q1 		$457 Hold
1
– – ﹤0.01% 718
2015
Q4 		$634 Hold
1
– – ﹤0.01% 569
2015
Q3 		$440 Buy
+1
New +$1.22K ﹤0.01% 718

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffa Wealth Management's ATRA Position: Q3 2017 in Review

Raffa Wealth Management sold out of Atara Biotherapeutics (ATRA) in Q3 2017, closing a stake of 2 shares — an estimated $672 sold.

Raffa Wealth Management first reported a position in ATRA in Q3 2015 and held it in 8 quarters. The position peaked at $986 in Q1 2017. 82 funds tracked by Wall St. Rank hold ATRA as of Q3 2017.

  • Raffa Wealth Management reported no remaining Atara Biotherapeutics position as of Q3 2017 after selling out during the quarter.
  • Raffa Wealth Management sold 2 Atara Biotherapeutics shares in Q3 2017, an estimated $672.
  • Raffa Wealth Management first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 8 quarters.
  • Raffa Wealth Management's Atara Biotherapeutics position peaked at $986 in Q1 2017.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2017.

Based on Raffa Wealth Management's 13F filing for Q3 2017, filed 27 Jul 2026.